Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Multi-dimensional omics approach to stratification of patients with low back pain (PAIN-OMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Belgium,Italy,United Kingdom,Germany,Croatia,France,Australia,Netherlands,United States
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2018-08-31
Duration (months): 60.0
Total project cost (EUR): 8550834.81
EU funding (EUR): 5998886.0
Participants: 12
Project status: CLOSED

Pain-OMICS is a multidisciplinary consortium of leading clinical, academic and SME researchers in pain and different omics technologies. Genome-wide association studies identified a number of loci associated with pain, but the level of knowledge about underlying mechanisms of different pain syndromes as well as individual variation in the disease course remains inadequate. Pain-OMICS will capitalise on its existing high quality clinical, genetic, biochemical and pharmacological data and biological samples on over 5000 well characterised patients with low-back pain (LBP) and controls available to our EU and US clinical partners. We will exploit novel technological approaches made available through the expertise and global leading position of our analytical partners. These comprise cutting edge genomic, epigenomic, glycomic, and activomic approaches which reflect signal transduction and membrane dynamics. We believe that the inclusion of these complementary analyses will elucidate pathways through which acute LBP fails to resolve and becomes chronic LBP. In addition, these approaches will reveal pathways and biomarkers of chronic pain through which individual differences affects symptoms and response to therapy. Participation of leading clinics on both sides of the Atlantic will enable replication of all finding in at least three independent large cohorts, as well as in prospective study and a large twin cohort. A complex systems biology approach will be used to integrate, interrogate and understand this multidimensional dataset in order to achieve the aims of identifying novel diagnostic and prognostic biomarkers as well as new targets for therapeutic intervention. The track record of achievement of our partners coupled to participation of research-intensive SMEs is a strong indication that the ambitious work programme will be achieved and provides a framework for rapid translation of research discoveries into solutions for the benefit of large numbers of patients.

Keywords: low-back pain,genomics,epigenomics,glycomics,activomics,systems biology,farmacogenomics
Aggression subtyping for improved insight and treatment innovation in psychiatric disorders (AGGRESSOTYPE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Spain,Germany,Germany,Norway,United States,Estonia,United Kingdom,Netherlands,Iceland,France,Switzerland,Germany,Netherlands,United Kingdom,Germany,Spain,Italy,Germany,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2018-10-31
Duration (months): 60.0
Total project cost (EUR): 7863785.6
EU funding (EUR): 6000000.0
Participants: 27
Project status: CLOSED

Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental subtypes, we investigate the aetiology of maladaptive aggression in paediatric conduct disorders most strongly predisposing to pathological aggression, ADHD and conduct disorder, and in the general population. We employ highly innovative approaches in humans and animal models and maximize the output from the project by optimally balancing the use of large, existing data sets with new data acquisition. Through this, we build a knowledge chain from molecule to behaviour, investigating known and novel genes, gene-networks and their epigenetic interactions, and mapping their mode of action from the molecular via the cellular to the brain-circuit level. This is accompanied by highly powered analyses of the neural substrates of the aggression subtypes. Based on innovative bioinformatic multimodal data integration, our interdisciplinary research will lead to novel, accurate algorithms for reliable aggression prediction, which will be validated in existing longitudinal studies in children and tested for their predictive value in adult outcome. In addition to this approach towards prevention, we test promising non-pharmacological biofeedback for personalised treatment and prevention of overt aggression. For the identification of novel pharmacological compounds in aggression treatment, we introduce a new animal model, the zebrafish. The Aggressotype consortium is based on successful existing collaborations. It includes experts in childhood and adult psychiatry and research-intensive SMEs ensuring maximal dissemination, clinical implementation and business development opportunities.

Keywords: impulsive/instrumental,adhd,conduct disorder,mri,pathway,optogenetics,epigenetics,zebrafish,biosensor,ipsc,whole genome sequencing,bioinformatics,prediction,biofeedback,pharmacological
Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology (BETACURE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,Netherlands,Switzerland,Germany,United Kingdom,Finland,France,Germany,Germany,Netherlands,Austria,Austria
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-04-01
End date: 2018-03-31
Duration (months): 48.0
Total project cost (EUR): 7873306.05
EU funding (EUR): 6000000.0
Participants: 18
Project status: CLOSED

Background: Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptable in relation to the lethal outcome of HH although massively reducing quality of life and also life expectancy. Aims and objectives: In order to significantly improve therapy of this awful disorder, we propose to develop a simultaneous imaging/therapy platform allowing diagnostic imaging as well as image guided surgical, photodynamic or radiopeptide therapy to selectively resect/destroy diseased beta cells. This platform will enable delivery of patient-individual tailored therapy, increasing cure rate while significantly reducing or even avoiding side effects. The platform will integrate information from pre-clinical imaging for optimal therapy planning with intra-operative imaging for image guided surgery. By implementation of extended field optical coherence tomography, information on a histopathological level will allow increased precision of therapy. Highly innovative photodynamic therapy will enable selective (endoscopic) destruction of diseased beta cells without resection of pancreatic tissue. Outcome: Our highly-innovative integrated imaging/therapy (“theranostic”) platform will allow diagnosis and monitoring of disease, support and guide therapeutic intervention, predict outcome of intervention and individual prognosis. This technology will massively improve therapy, especially in infants, by improving cure rates while significantly reducing morbidity for improved quality of life and increased life expectancy. We will contribute to the goals of the International Rare Diseases Research Consortium (IRDiRC): 200 new therapies.

Keywords: hyperinsulinaemic hypoglycaemia congenital hyperinsulinism insulinoma image guided surgery photodynamic therapy molecular imaging radiopeptide peptide receptor radiotherapy
Developing and Testing a novel, low-cost, effective HOOKworm VACcine to Control Human Hookworm Infection in endemic countries (HOOKVAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,United States,Germany,Gabon,Belgium,United Kingdom,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2019-03-31
Duration (months): 66.0
Total project cost (EUR): 7672532.26
EU funding (EUR): 5999983.0
Participants: 9
Project status: CLOSED

Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease, and among the top 3 in terms of lost Disability-Adjusted Life Years. HOOKVAC will be developing the first and only vaccine for human hookworm infection. A low-cost vaccine candidate will be clinically tested for the first time in an African disease endemic population. The project will have 3 clinical trials: HV01: in healthy adults between the ages of 18 and 50 with co-administered Na-GST-1 and Na-APR-1 adjuvanted with GLA-AF, HV02: in healthy children between the ages of 6 and 10 with co-administered Na-GST-1 and Na-APR-1 adjuvanted with GLA-AF and HV03: in healthy adults between the ages of 18 and 50 with Na-GST-1 adjuvanted with CPG10104. All 3 studies will be conducted in Gabon in a very typical setting within the Central African rainforest belt, where the incidence of hookworm infections is 30%. Inspired by preparatory research, HOOKVAC believes that it can develop the vaccine with at least 80% efficacy against moderate and heavy hookworm infections that lasts at five years after immunization. Cost effectiveness modelling has shown that such a vaccine will significantly improve the efficacy of the current mass drug administration programs. HOOKVAC will play a crucial role in advancing toward large scale efficacy studies in African endemic areas. Via a program of 48 months with 6 work packages, HOOKVAC will address 4 main objectives: (1) establish safety and immunogenicity of the vaccine candidate in an endemic population (2) improve the manufacturing process (3) provide clinical proof of concept (4) improve accessibility of the vaccine in endemic areas. The involvement of European SMEs in the project is a critical component to advancing a successful vaccine, and an integral part of adding private sector know-how and scientific expertise to the project. This will inspire other European SMEs to become more involved in public/private vaccine product development for neglected infectious diseases. By doing so, HOOKVAC will fuel a follow-up programme for further development of the vaccine towards into a licensed product.

Keywords: hookworm,vaccine,pdp,product development partnership,neglected tropical diseases,clinical trials,effectiveness,safety
Microbubble driven multimodal imaging and theranostics for gliomas (THERAGLIO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,Israel,Italy,Hungary,Germany,Spain,Spain,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2018-09-30
Duration (months): 60.0
Total project cost (EUR): 10283794.66
EU funding (EUR): 5998890.0
Participants: 12
Project status: CLOSED

Microbubbles (MBs) are used as contrast agent in ultrasound (US) imaging for a variety of tumours while little has been done for glioblastomas, a rare cancer. Intraoperative Contrast-Enhanced US-imaging (CEUS) using lipidic MBs hold promises in increasing extent of resection of such tumors. Furthermore, MBs gained recently interest as a delivery system for drugs. We will develop a new generation of multimodal MBs, acting simultaneously as contrast agent for Magnetic Resonance Imaging (MRI), CEUS and intra-operative fluorescence for multimodal real-time image-guided resection of glioblastomas. We plan to transform MBs by replacing air with perfluorcarbon gas and/or attaching super-paramagnetic-iron-oxide nanoparticles for MRI visualization. We will also engineer MBs with RGD-motif to adhere selectively to pathological endothelial integrins and with near-infrared fluorophores for simultaneous US deep tissue imaging and direct microscopic tumour visualization to maximize resection. A software will be developed for integration of preoperative MRI, intraoperative US and microscopic imaging. We will focus on lipidic and polymeric MBs. Lipidic MBs are approved for clinical use; therefore, once modified, more easily translatable into clinical applications to reach a feasibility study on patients. In addition, we will improve multifunctional, polymer-based MBs. Multifunctional-stabilized-polymer-MBs are more stable and more versatile to be complexed with different molecules or nanoparticles as compared to lipidic Mbs and will be designed as a platform for delivering standard and/or experimental chemotherapeutic drugs to the tumour, acting as an innovative way for local targeting and delivering any kind of agent to a specific target, in a safe and controlled fashion. This would be a big step forward in the field of personalized medicine, moving standard MG image-guided treatment towards more effective, safer, molecular-based tailored interventions to specific patients.

Keywords: microbubbles,contrast-agent,ultrasound,neurosurgery,polymers,nanoparticles,local delivery
Human stem cell applications for the treatment of hearing loss (OTOSTEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Switzerland,United Kingdom,France,Sweden,United States,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2017-10-31
Duration (months): 48.0
Total project cost (EUR): 7892595.6
EU funding (EUR): 5999784.0
Participants: 10
Project status: CLOSED

Hearing impairment is the most frequent human sensory deficit and is mainly caused by the irreversible loss of neurosensory cells in the cochlea. The lack of human otic cell models represents a significant roadblock that has hampered the development of drug-based or cell-based therapies for the treatment of hearing loss. In a collaborative effort under this proposal we wish to devise approaches to generate human otic progenitors and differentiated otic cells from different human stem cell sources. We have devised guidance protocols for mouse and human embryonic and reprogrammed stem cells toward inner ear cell types that make use of principles of early germ layer formation and otic induction. A limitation is the efficacy of otic progenitor cell generation. Purification techniques for human otic progenitors from ES/iPS cell sources and in addition from native human otic tissues from fetal and adult stages will will serve the dual purpose for one to enable the development of novel bioassays for drug screens, as well as generating cells with decreased tumorigenicity for cell transplantation studies in in vivo animal models. New hit compounds identified from screening efforts will be tested and validated further in established organ culture models. The identification of relevant candidate compounds will be further developed as lead drug candidates in noise and ototoxic drug induced in vivo models. The scope of this stem cell technology development requires a collaborative team effort, with groups that have substantial combined experience in human ES/iPS cell work, inner ear stem cell biology, high-throughput assay development, and in translating research findings into the clinic as well as into the biotechnology realm. Within the consortium there exists an established translational route from bench to bedside for the commercial development of human otic stem cell derived technology towards inner ear medical applications aiming at the restoration of hearing function.

Keywords: hearing impairment,cochlea,human otic cell models,biomarkers,bioassays,human embryonic stem cells human induced pluripotent stem cells,organ of corti stem cells,spiral ganglion stem cells
REduction of DIsease risk” CLAIMs on food and drinks (REDICLAIM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: United Kingdom,Slovenia,Denmark
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2017-04-30
Duration (months): 42.0
Total project cost (EUR): 662572.8
EU funding (EUR): 499824.0
Participants: 4
Project status: CLOSED

REDICLAIM (Understanding the impact of legislation on “REduction of DIsease risk” CLAIMs on food and drinks) seeks to understand the way in which the European Regulation (EC) No. 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods and associated legislation has had and continues to have an impact on the substantiation and use of “reduction of disease risk” claims on food and drinks. To achieve this REDICLAIM will: (1) Seek to understand the (a) main issues and hurdles concerning substantiation and use of “reduction of disease risk” claims on food and drinks; (b) level of awareness about legal obligations with regard to “reduction of disease risk” claims on food and drinks among the relevant stakeholders; and (2) Produce a three-fold study of the impact of nutrition and health claims legislation specific to “reduction of disease risk” claims on food and drinks on: (a) The claim substantiation process, (b) Health research and/or innovation in the food chain, and (c) Nutrition economic models to determine health impact. REDICLAIM results will contribute to: (1) the development of an evidence base of the process by which health and nutrition claims are made and controlled by regulatory frameworks; (2) the effectiveness of their control by regulation; (3) the establishment of recommendations for government, industry and the scientific community with a view to conducting the necessary research and development of such products. The aim of this will be to achieve both effective compliance with better regulation and, to contribute to the enhancement of innovative and competitive products.

Keywords: legislation,health claims,food,drinks,nutrition,substantiation,innovation,reduction of disease risk,food chain
Multicentre Preclinical Animal Research Team (MULTI-PART)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: United Kingdom,United Kingdom,Germany,Netherlands,Spain,France,Switzerland,United Kingdom,Spain,United Kingdom,Australia
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2015-08-31
Duration (months): 24.0
Total project cost (EUR): 557480.12
EU funding (EUR): 497781.0
Participants: 12
Project status: CLOSED

Millions of Europeans still suffer the consequences of neurological disease, but the number of new drugs coming to market continues to fall. Reasons for the failure of stroke drug efficacy to translate from animals to clinical trials is probably best studied, but the problem is widespread. The economic and social costs of translational failure are substantial; a new approach to translational medicine is required. We propose the development of a capacity for multi-centre animal studies to address issues of limited validity; poor generalisability; and inadequate sample size. This will include central randomisation, outcome adjudication, and monitoring of laboratory practice; planned heterogeneity between sites to increase generalisability; and the capacity quickly to deliver large studies. Our data will be more reliable, reducing the need for further animal studies; and because clinical trials will be founded on better evidence the risk to participants will be lower. This idea has been broadly welcomed, and the next stage is to establish a framework within which this may be achieved. Our objective is to engage with all partners to build consensus around the feasibility, structure, composition and operation of multi-centre consortia. Issues include the role of industry and regulators; whether the capacity to deliver such studies exists; the statistical analysis to be used; and ethical, legal and governance issues. This consensus will be achieved through a series of themed meetings involving the applicants and others; the development of a detailed plan for such a consortium; and the validation of that plan with a specially constituted Scientific Advisory Board. We will then seek funding for the delivery of multi-centre animal studies based on this plan to allow its delivery. The applicants bring together substantial relevant expertise. This is a high-risk project, but the potential research, economic and health gains both in Europe and beyond are huge.

Keywords: translation,international cooperation,phase iii preclinical studies,brain research,experimental validity
Systems Biology to Identify Molecular Targets for Vascular Disease Treatment (SYSVASC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Austria,Germany,Germany,United Kingdom,France,Australia,United Kingdom,Ireland,Greece,Germany,Switzerland,Canada,Austria,United Kingdom,Netherlands,Austria,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2018-01-31
Duration (months): 48.0
Total project cost (EUR): 8350348.27
EU funding (EUR): 5976413.0
Participants: 19
Project status: CLOSED

Asymptomatic vascular damage accumulates for years before patients are identified and subjected to therapeutic measures. The limited knowledge on early vascular disease pathophysiology is reflected in the lack of therapeutic options. SysVasc aims to overcome this limitation by mounting a comprehensive systems medicine approach to elucidate pathological mechanisms, which will yield molecular targets for therapeutic intervention. The consortium is based on established multidisciplinary European research networks, including specialists in pre-clinical and clinical research, omics technologies, and systems biology from research intensive SMEs and academia; partners synergistically provide access to an extensive number of selected population-based cohorts and associated datasets, cutting edge modeling and simulation methods, and established cardiovascular disease (CVD) animal models and patient cohorts. The coordinated application of these tools and know-how will identify pathophysiological mechanisms and key molecules responsible for onset and progression of CVD and validate their potential to serve as molecular targets for therapeutic intervention. To this end, the consortium will also use unique resources to evaluate molecular homology between the available model systems and human disease, which will yield reliable essential preclinical research tools to explore proof of concepts for therapeutic intervention studies and ultimately translate relevant results into novel therapeutic approaches. Collectively, SysVasc will identify and validate novel biology-driven key molecular targets for CVD treatment. Major scientific, societal and economic impact is expected including, but not limited to, providing a valuable resource to further CVD research, and enhance competitiveness of participating SMEs and European health industry in general by translating knowledge into “innovative services” in therapeutic target and drug research.

Keywords: cardiovascular disease,molecular therapeutic target,genomics,proteomics,metabolomics,systems medicine,animal models